Abstract: An apparatus for manufacturing molten iron includes: an iron ore-mixing/pre-reducing furnace receiving and mixing natural iron ore and oxidized iron ore to form a mixture, and heating or pre-reducing the mixture using a reaction gas to form a pre-heated or pre-reduced iron ore; an iron ore reduction furnace receiving the pre-heated or pre-reduced iron ore iron ore and reducing the pre-heated or pre-reduced iron ore using a reduction gas to form a reduced iron ore and produce the reaction gas; a molten gasification furnace receiving coal and the reduced iron ore and producing molten iron and the reduction gas; and an iron ore oxidizing-burning furnace receiving part of the reduced iron ore discharged from the iron ore reduction furnace and oxidizing the received reduced iron ore to produce the oxidized iron ore. The oxidized iron ore is supplied to the iron ore-mixing/pre-reducing furnace.

Abstract: An apparatus for manufacturing molten iron includes: an iron ore-mixing/pre-reducing furnace receiving and mixing natural iron ore and oxidized iron ore supplied from an iron ore oxidizing-burning furnace, and heating or pre-reducing iron ore using flue gas supplied from an iron ore reduction furnace. The iron ore reduction furnace receives pre-processed iron ore discharged from the iron ore-mixing/pre-reducing furnace or partially reduced iron ore, and reduces the iron ore using a reduction gas discharged from a molten gasification furnace that receives coal and some of reduced iron produced by the iron ore reduction furnace and produces molten iron and a reduction gas to be supplied to the iron ore reduction furnace. The iron ore oxidizing-burning furnace receives new iron ore and some of reduced iron and changes the new iron ore into oxidized iron ore including oxygen by burning the new iron ore and the reduced iron with air.

Abstract: A sustained-release composition for oral administration of a drug, comprising the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 hours or more. Due to rapid gel hydration without forming a non-gelated core, the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility.

Abstract: There are provided a coating composition for siliconizing, and a method for manufacturing a high silicon electrical steel sheet using the same. The coating composition includes: a Fe—Si-based composite compound sintered powder having a grain size of ?325 mesh and containing 20-70% silicon by weight; and a colloidal silica solution containing 15-30 part by weight of silica solid matter with respect to 100 part by weight of the sintered powder.

Abstract: A method for manufacturing a high silicon grain-oriented electrical steel sheet. In a method for manufacturing a high silicon grain-oriented electrical steel sheet, comprising the steps of: reheating and hot-rolling a steel slab to produce a hot-rolled steel sheet; annealing the hot-rolled sheet and cold rolling the annealed steel sheet so as to adjust a thickness of the steel sheet; decarburization annealing the cold rolled steel sheet; and finish-annealing the decarburization annealed steel sheet for secondary recrystallization, the improved method further comprising the step of: coating a powder coating agent for siliconization on a surface of the decarburization annealed steel sheet in a slurry state, the powder coating agent including 100 part by weight of MgO powder and 0.

Abstract: The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby, the paclitaxel solid dispersion being highly homogeneous and showing an improved solubility, thereby being effectively used for the preparation of paclitaxel injection and oral preparation having a high bioavailability.

Abstract: A microemulsion concentrate comprising a water-insoluble anti-cold drug, a surfactant and an oil, which is prepared by a method comprising: (a) dissolving the water-insoluble anti-cold drug in a co-surfactant to obtain a homogeneous drug solution; (b) adding the surfactant and the oil in the drug solution to obtain a microemulsion pre-concentrate; and (c) removing the co-surfactant from the pre-concentrate, contains emulsified drug microparticles which are stable toward pH change and therefore, provides improved bioavaiability of the drug when orally administered.

Abstract: A method for manufacturing a high silicon grain-oriented electrical steel sheet. In a method for manufacturing a high silicon grain-oriented electrical steel sheet, comprising the steps of: reheating and hot-rolling a steel slab to produce a hot-rolled steel sheet; annealing the hot-rolled sheet and cold rolling the annealed steel sheet so as to adjust a thickness of the steel sheet; decarburization annealing the cold rolled steel sheet; and finish-annealing the decarburization annealed steel sheet for secondary recrystallization, the improved method further comprising the step of: coating a powder coating agent for siliconization on a surface of the decarburization annealed steel sheet in a slurry state, the powder coating agent including 100 part by weight of MgO powder and 0.

Abstract: There are provided a coating composition for siliconizing, and a method for manufacturing a high silicon electrical steel sheet using the same. The coating composition includes: a Fe—Si-based composite compound sintered powder having a grain size of ?325 mesh and containing 20-70% silicon by weight; and a colloidal silica solution containing 15 -30 part by weight of silica solid matter with respect to 100 part by weight of the sintered powder.

Abstract: Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cardiovascular diseases.

Abstract: A viscous and glassy composition for oral administration comprising itraconazole, an acidifing agent, an amphiphilic additive, a surfactant and an oil provides a high in vivo bioavailability of itraconazole which is little influenced by ingested food.

Abstract: Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cadiovacular diseases.

Abstract: A sustained-release composition for oral administration of a drug, comprising the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 hours or more owing to the fact that the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility due to rapid gel hydration without forming a non-gelated core.

Abstract: The present invention relates to a process for the preparation of a tablet having an enhanced strength as well as a high disintegrating rate in the oral cavity, which comprises: spray-drying an active ingredient to obtain a spray-dried particulate containing the active ingredient; mixing the spray-dried particulate, a sublimable substance suitable for oral administration, a poly(ethylene glycol), and a pharmaceutically acceptable additive; tableting the mixture; and drying the resulting tablet to sublime the sublimable substance until the tablet becomes porous.

Abstract: An oral micro-emulsion composition comprising a Carduus marianus extract, silybin or a silybin derivative; an organic solvent; a surfactant; and an oil provides a high in vivo bioavailability of silybin.

Abstract: The bioavailability of a drug which is not readily absorbed in the digestive tract can be greatly enhanced by administering an oral composition comprising a drug and a compound of formula (I): 1

Abstract: A tablet having an enhanced strength as well as a high disintegrating rate in the oral cavity is prepared by mixing a spray-dried particulate containing an active ingredient, a sublimable substance suitable for oral administration, a poly(ethylene glycol), and a pharmaceutically acceptable additive; tableting the mixture; and drying the resulting tablet to sublime the sublimable substance until the tablet becomes porous.

Abstract: An oral micro-emulsion composition comprising a Carduus marianus extract, silybin or a silybin derivative; an organic solvent; a surfactant; and an oil provides a high in vivo bioavailability of silybin.

Abstract: A non-crystalline cefuroxime axetil solid dispersant showing no absorption peak on a Differential Scanning Calorimetry scan is prepared by (a) dissolving cefuroxime axetil and a surfactant in an organic solvent; (b) suspending a water-insoluble inorganic carrier in the resulting solution; and (c) drying the resulting suspension to remove the organic solvent, said solid dispersant having an improved bioavailability and stability of cefuroxime axetil and being useful for the preparation of a pharmaceutical composition for oral administration.

Abstract: An antifungal oral composition comprising a fused mixture of itraconazole and phosphoric acid provides a high in vivo bioavailability of itraconazole.